Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Plasma cell 1

Conditions

Multiple Myeloma 175Recurrence 32Neoplasms, Plasma Cell 16Lymphoma 11Waldenstrom Macroglobulinemia 6Neoplasms 6Lymphoma, Mantle-Cell 6Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Smoldering Multiple Myeloma 4Leukemia 4Small Cell Lung Carcinoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, T-Cell, Peripheral 3Lymphoma, B-Cell, Marginal Zone 3Leukemia, Plasma Cell 3Hodgkin Disease 3Hematologic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Disease 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Sezary Syndrome 1Salivary Gland Adenoma, Pleomorphic 1

Interventions

Cyclophosphamide 87fludarabine 74Tacrolimus 45fludarabine phosphate 44Mycophenolic Acid 42Whole-Body Irradiation 41Busulfan 35Melphalan 31Antilymphocyte Serum 24thymoglobulin 22Methotrexate 22Rituximab 21venetoclax 20Standard of Care 20Sirolimus 20Azacitidine 20Thiotepa 19Stem Cell Transplantation 18Granulocyte Colony-Stimulating Factor 18Practice Guidelines as Topic 16Cytarabine 16Nivolumab 15Filgrastim 15Dexamethasone 14Cyclosporine 13Bortezomib 13Mesna 12Peripheral Blood Stem Cell Transplantation 11trametinib 10Specimen Handling 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Hematologic Neoplasms × carfilzomib × Clear all
NCT02145403 2022-01-03

Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies

University of Michigan Rogel Cancer Center

Phase 1/2 Completed
53 enrolled 17 charts
LymphoidOther hematologic neoplasmPlasma cell

Graft vs Host Disease, Leukemia, Lymphoma, Multiple Myeloma, Recurrence, Hematologic Neoplasms

NCT01949545 2017-05-02

Study of the Pharmacokinetics and Safety of Carfilzomib in Patients With Advanced Malignancies and Hepatic Impairment

Amgen

Phase 1 Completed
46 enrolled 45 charts
Other hematologic neoplasm

Hematologic Neoplasms

NCT01212380 2016-05-09

Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)

Ohio State University Comprehensive Cancer Center

Phase 1 Completed
21 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡